Glaxo: European Commission Grants Marketing Authorization for Pazopanib

GlaxoSmithKline said the European Commission has granted pazopanib marketing authorization for the treatment of patients with advanced soft tissue sarcoma or aSTS who have received prior chemotherapy or have progressed within 12 months after adjuvant therapy.
Fox Business